Warning: The NCBI web site requires JavaScript to function. more...
Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.
Leary AF, Sirohi B, Johnston SR.
Breast Cancer Res. 2007;9(5):112.
Related citations
Endocrine therapy and other targeted therapies for metastatic breast cancer.
Hussain SA, Palmer DH, Moon S, Rea DW.
Expert Rev Anticancer Ther. 2004 Dec;4(6):1179-95. Review.
Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.
Johnston SR, Martin LA, Head J, Smith I, Dowsett M.
J Steroid Biochem Mol Biol. 2005 May;95(1-5):173-81. Review.
Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.
Adv Exp Med Biol. 2007;608:1-22. Review.
Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance.
Johnston SR.
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S145-57. Review.
Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?
Johnston SR, Leary A, Martin LA, Smith IE, Dowsett M.
Cancer. 2008 Feb 1;112(3 Suppl):710-7.
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Prat A, Baselga J.
Nat Clin Pract Oncol. 2008 Sep;5(9):531-42. Epub 2008 Jul 8. Review.
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
Come SE, Buzdar AU, Ingle JN, Johnston SR, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE.
Cancer. 2008 Feb 1;112(3 Suppl):673-8.
Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):889s-99s. Review.
Factors predictive of response to hormone therapy in breast cancer.
Rastelli F, Crispino S.
Tumori. 2008 May-Jun;94(3):370-83. Review.
Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
Bedard PL, Freedman OC, Howell A, Clemons M.
Breast Cancer Res Treat. 2008 Apr;108(3):307-17. Epub 2007 May 22. Review.
New strategies in estrogen receptor-positive breast cancer.
Clin Cancer Res. 2010 Apr 1;16(7):1979-87. Epub 2010 Mar 23. Review.
Endocrine therapy of metastatic breast cancer.
Rodríguez Lajusticia L, Martín Jiménez M, López-Tarruella Cobo S.
Clin Transl Oncol. 2008 Aug;10(8):462-7. Review.
Enhancing the efficacy of hormonal agents with selected targeted agents.
Clin Breast Cancer. 2009 Jun;9 Suppl 1:S28-36. Review.
Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S, Schiff R.
Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S15-24. Review.
Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
Leary A, Dowsett M.
Br J Cancer. 2006 Sep 18;95(6):661-6. Epub 2006 Aug 22. Review.
Predicting endocrine therapy responsiveness in breast cancer.
Ma CX, Sanchez CG, Ellis MJ.
Oncology (Williston Park). 2009 Feb;23(2):133-42. Review.
Addressing the future: combination with targeted therapies, adjuvant setting and beyond.
Goss PE.
Anticancer Drugs. 2008 Mar;19 Suppl 2:S3-5. Review.
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.
J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. Epub 2008 Sep 23.
Endocrine therapy for the treatment of postmenopausal women with breast cancer.
Harichand-Herdt S, Zelnak A, O'Regan R.
Expert Rev Anticancer Ther. 2009 Feb;9(2):187-98. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on